Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

SOLO2/ENGOT-Ov21 investigators

Research output: Contribution to journal › Article › peer-review

671 Scopus citations

Fingerprint

Dive into the research topics of 'Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences